Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen DC Vaccine and T-cell Therapy in Solid Tumors
NCT05235607Phase 1Unknown
- Sponsor
- Sichuan University
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in melanoma, bladder cancer and colorectal cancer (CRC), sponsored by Sichuan University. Primary endpoint: Number of participants with treatment-related adverse events. Status: unknown.
02
Conditions
melanomabladder cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05235607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05235607.